IHC for calretinin was applied on all 41 cases (Table 4). After application of calretinin IHC, out of 41 cases, 30 (73.17%) cases were confirmed as HD while the remaining 11 (26.82%) cases were confirmed as NHD, hence all suspicious HD cases had been confirmed and categorized in HD and NHD groups (Table 4). This evidence concerns the gene CALB2 and Huntington disease.